ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity (2020 - 2026)

ARS Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $287.6 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $287.6 million, down 12.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 16.41% YoY), and the FY2025 annual result was $327.7 million, down 6.69% from the prior year.
• Liabilities and Shareholders Equity came in at $287.6 million for Q1 2026 at ARS Pharmaceuticals, down from $327.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $372.8 million in Q3 2025 to a low of $217.6 million in Q3 2024.
• The 5-year median for Liabilities and Shareholders Equity is $281.4 million (2022), against an average of $283.4 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 358.02% in 2022, while the deepest fall reached 23.12% in 2022.
• ARS Pharmaceuticals' Liabilities and Shareholders Equity stood at $281.4 million in 2022, then dropped by 17.14% to $233.2 million in 2023, then jumped by 50.59% to $351.2 million in 2024, then retreated by 6.69% to $327.7 million in 2025, then declined by 12.23% to $287.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $287.6 million (Q1 2026), $327.7 million (Q4 2025), and $372.8 million (Q3 2025), per Business Quant data.